NEW YORK, Sept. 20, 2016 /PRNewswire/ -- Faruqi &
Faruqi, LLP, a leading national securities law firm, is
investigating potential securities fraud at Spectrum
Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ:
SPPI).
The investigation focuses on whether the Company and its
executives violated federal securities laws by issuing materially
misleading information about the Company. Specifically, on
September 14, 2016, the U.S. Food and
Drug Administration's Oncologic Drugs Advisory Committee (ODAC)
voted against approval of Qapzola. On this news, the
Company's stock declined.
On September 16, 2016,
TheStreet published an article that revealed in a
December 2012 meeting, the FDA
advised Spectrum not to file a New Drug Application for its bladder
cancer drug. Although the FDA gave this advice, the Company
misrepresented to investors in a May
2015 conference call that "we took this data, met with the
FDA, and our understanding is and our decision is that we can go
ahead and file the NDA with this drug." According to the article,
that was not a fully truthful summary of the FDA's guidance to the
Company.
Request more information now by clicking here:
www.faruqilaw.com/SPPI. There is no cost or obligation to
you.
Take Action
If you invested in Spectrum Pharmaceuticals stock or options and
would like to discuss your legal rights, visit
www.faruqilaw.com/SPPI. You can also contact us by calling
Richard Gonnello toll free at
877-247-4292 or at 212-983-9330 or by sending an e-mail to
rgonnello@faruqilaw.com. Faruqi & Faruqi, LLP also
encourages anyone with information regarding Spectrum
Pharmaceuticals' conduct to contact the firm, including
whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this
advertisement is Faruqi & Faruqi, LLP
(www.faruqilaw.com). Prior results do not guarantee or
predict a similar outcome with respect to any future matter.
We welcome the opportunity to discuss your particular case.
All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello,
Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330
Logo -
http://photos.prnewswire.com/prnh/20120119/MM38856LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/spectrum-pharmaceuticals-notification-faruqi--faruqi-llp-encourages-investors-who-suffered-losses-in-excess-of-100000-investing-in-spectrum-pharmaceuticals-inc-to-contact-the-firm-300330539.html
SOURCE Faruqi & Faruqi, LLP